JP2011500697A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500697A5 JP2011500697A5 JP2010530054A JP2010530054A JP2011500697A5 JP 2011500697 A5 JP2011500697 A5 JP 2011500697A5 JP 2010530054 A JP2010530054 A JP 2010530054A JP 2010530054 A JP2010530054 A JP 2010530054A JP 2011500697 A5 JP2011500697 A5 JP 2011500697A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- phenyl
- bipyrrolidinyl
- amide
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000001257 hydrogen Substances 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- -1 n- hexyl Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 239000004202 carbamide Substances 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 125000003047 N-acetyl group Chemical group 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- STUHQDIOZQUPGP-UHFFFAOYSA-N morpholin-4-ium-4-carboxylate Chemical compound OC(=O)N1CCOCC1 STUHQDIOZQUPGP-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- TXYHNJMNQMYNTO-UHFFFAOYSA-N 1-(3,5-dichlorophenyl)-3-[2-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]urea Chemical compound CC1CCCN1C1CN(C=2C=C(C)C(NC(=O)NC=3C=C(Cl)C=C(Cl)C=3)=CC=2)CC1 TXYHNJMNQMYNTO-UHFFFAOYSA-N 0.000 claims 1
- RHEVIGLLTLURAQ-UHFFFAOYSA-N 1-(3,5-dichlorophenyl)-3-[3-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]urea Chemical compound CC1CCCN1C1CN(C=2C(=CC(NC(=O)NC=3C=C(Cl)C=C(Cl)C=3)=CC=2)C)CC1 RHEVIGLLTLURAQ-UHFFFAOYSA-N 0.000 claims 1
- GURFDWVYTCEBLB-UHFFFAOYSA-N 1-(3,5-dichlorophenyl)-3-[4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]urea Chemical compound CC1CCCN1C1CN(C=2C=CC(NC(=O)NC=3C=C(Cl)C=C(Cl)C=3)=CC=2)CC1 GURFDWVYTCEBLB-UHFFFAOYSA-N 0.000 claims 1
- UCSCBDCRYZONHX-UHFFFAOYSA-N 1-(3-cyanophenyl)-3-[3-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]urea Chemical compound CC1CCCN1C1CN(C=2C(=CC(NC(=O)NC=3C=C(C=CC=3)C#N)=CC=2)C)CC1 UCSCBDCRYZONHX-UHFFFAOYSA-N 0.000 claims 1
- JEMKFSIFMPGUKZ-UHFFFAOYSA-N 1-(3-cyanophenyl)-3-[4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]urea Chemical compound CC1CCCN1C1CN(C=2C=CC(NC(=O)NC=3C=C(C=CC=3)C#N)=CC=2)CC1 JEMKFSIFMPGUKZ-UHFFFAOYSA-N 0.000 claims 1
- KBIMBEHOSLKBMG-UHFFFAOYSA-N 1-[(3,5-dichlorophenyl)methyl]-3-[3-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]urea Chemical compound CC1CCCN1C1CN(C=2C(=CC(NC(=O)NCC=3C=C(Cl)C=C(Cl)C=3)=CC=2)C)CC1 KBIMBEHOSLKBMG-UHFFFAOYSA-N 0.000 claims 1
- ZSUUYMKBUDJXPU-UHFFFAOYSA-N 1-[(3,5-dichlorophenyl)methyl]-3-[4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]-2-(trifluoromethyl)phenyl]urea Chemical compound CC1CCCN1C1CN(C=2C=C(C(NC(=O)NCC=3C=C(Cl)C=C(Cl)C=3)=CC=2)C(F)(F)F)CC1 ZSUUYMKBUDJXPU-UHFFFAOYSA-N 0.000 claims 1
- CCDWSMJPLNHEDZ-UHFFFAOYSA-N 1-[3-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]-3-(thiophen-2-ylmethyl)urea Chemical compound CC1CCCN1C1CN(C=2C(=CC(NC(=O)NCC=3SC=CC=3)=CC=2)C)CC1 CCDWSMJPLNHEDZ-UHFFFAOYSA-N 0.000 claims 1
- MWATVQYCLGPJBC-UHFFFAOYSA-N 1-[4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]-3-(thiophen-2-ylmethyl)urea Chemical compound CC1CCCN1C1CN(C=2C=CC(NC(=O)NCC=3SC=CC=3)=CC=2)CC1 MWATVQYCLGPJBC-UHFFFAOYSA-N 0.000 claims 1
- CTQMYZRBBXTDJI-UHFFFAOYSA-N 1-cyclohexyl-3-[2-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]urea Chemical compound CC1CCCN1C1CN(C=2C=C(C)C(NC(=O)NC3CCCCC3)=CC=2)CC1 CTQMYZRBBXTDJI-UHFFFAOYSA-N 0.000 claims 1
- VMHFMQVWQIGSIQ-UHFFFAOYSA-N 1-cyclohexyl-3-[3-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]urea Chemical compound CC1CCCN1C1CN(C=2C(=CC(NC(=O)NC3CCCCC3)=CC=2)C)CC1 VMHFMQVWQIGSIQ-UHFFFAOYSA-N 0.000 claims 1
- ZFXGNBOXQNGCFE-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]urea Chemical compound CC1CCCN1C1CN(C=2C=CC(NC(=O)NC3CCCCC3)=CC=2)CC1 ZFXGNBOXQNGCFE-UHFFFAOYSA-N 0.000 claims 1
- XPNGRYZHYABEFS-UHFFFAOYSA-N 3-[acetyl(methyl)amino]-n-[3-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]pyrrolidine-1-carboxamide Chemical compound CC1CCCN1C1CN(C=2C(=CC(NC(=O)N3CC(CC3)N(C)C(C)=O)=CC=2)C)CC1 XPNGRYZHYABEFS-UHFFFAOYSA-N 0.000 claims 1
- QIACIVDGXFNLRA-UHFFFAOYSA-N 3-[acetyl(methyl)amino]-n-[4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]pyrrolidine-1-carboxamide Chemical compound CC1CCCN1C1CN(C=2C=CC(NC(=O)N3CC(CC3)N(C)C(C)=O)=CC=2)CC1 QIACIVDGXFNLRA-UHFFFAOYSA-N 0.000 claims 1
- QVEYYVHLQBRQNF-UHFFFAOYSA-N 4-acetyl-n-[3-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]piperazine-1-carboxamide Chemical compound CC1CCCN1C1CN(C=2C(=CC(NC(=O)N3CCN(CC3)C(C)=O)=CC=2)C)CC1 QVEYYVHLQBRQNF-UHFFFAOYSA-N 0.000 claims 1
- BCCVUKGKQRRJOM-UHFFFAOYSA-N 4-acetyl-n-[4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]piperazine-1-carboxamide Chemical compound CC1CCCN1C1CN(C=2C=CC(NC(=O)N3CCN(CC3)C(C)=O)=CC=2)CC1 BCCVUKGKQRRJOM-UHFFFAOYSA-N 0.000 claims 1
- NXMHCJSGJBPRQM-UHFFFAOYSA-N 4-ethylpiperazine-1-carboxylic acid Chemical compound CCN1CCN(C(O)=O)CC1 NXMHCJSGJBPRQM-UHFFFAOYSA-N 0.000 claims 1
- PHOGKWBKNQASCX-UHFFFAOYSA-N 4-methyl-n-[2-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]piperazine-1-carboxamide Chemical compound CC1CCCN1C1CN(C=2C=C(C)C(NC(=O)N3CCN(C)CC3)=CC=2)CC1 PHOGKWBKNQASCX-UHFFFAOYSA-N 0.000 claims 1
- XIGBTIXFXCZLOP-UHFFFAOYSA-N 4-methyl-n-[3-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]piperazine-1-carboxamide Chemical compound CC1CCCN1C1CN(C=2C(=CC(NC(=O)N3CCN(C)CC3)=CC=2)C)CC1 XIGBTIXFXCZLOP-UHFFFAOYSA-N 0.000 claims 1
- WGDBSIUKEGGNAD-UHFFFAOYSA-N 4-methyl-n-[4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]piperazine-1-carboxamide Chemical compound CC1CCCN1C1CN(C=2C=CC(NC(=O)N3CCN(C)CC3)=CC=2)CC1 WGDBSIUKEGGNAD-UHFFFAOYSA-N 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 206010024264 Lethargy Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000032140 Sleepiness Diseases 0.000 claims 1
- 206010041349 Somnolence Diseases 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- FZUWGYJOMCWJQG-UHFFFAOYSA-N n-[2-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]-1,3-dihydroisoindole-2-carboxamide Chemical compound CC1CCCN1C1CN(C=2C=C(C)C(NC(=O)N3CC4=CC=CC=C4C3)=CC=2)CC1 FZUWGYJOMCWJQG-UHFFFAOYSA-N 0.000 claims 1
- STGOJJLVUNZUKI-UHFFFAOYSA-N n-[3-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]-1,3-dihydroisoindole-2-carboxamide Chemical compound CC1CCCN1C1CN(C=2C(=CC(NC(=O)N3CC4=CC=CC=C4C3)=CC=2)C)CC1 STGOJJLVUNZUKI-UHFFFAOYSA-N 0.000 claims 1
- CDFWMRLTDLRZNL-UHFFFAOYSA-N n-[3-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]piperidine-1-carboxamide Chemical compound CC1CCCN1C1CN(C=2C(=CC(NC(=O)N3CCCCC3)=CC=2)C)CC1 CDFWMRLTDLRZNL-UHFFFAOYSA-N 0.000 claims 1
- HBWGNGFOCQPSDC-UHFFFAOYSA-N n-[4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]-1,3-dihydroisoindole-2-carboxamide Chemical compound CC1CCCN1C1CN(C=2C=CC(NC(=O)N3CC4=CC=CC=C4C3)=CC=2)CC1 HBWGNGFOCQPSDC-UHFFFAOYSA-N 0.000 claims 1
- OSBYOAIKJPMFDA-UHFFFAOYSA-N n-[4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]-4-phenylpiperazine-1-carboxamide Chemical compound CC1CCCN1C1CN(C=2C=CC(NC(=O)N3CCN(CC3)C=3C=CC=CC=3)=CC=2)CC1 OSBYOAIKJPMFDA-UHFFFAOYSA-N 0.000 claims 1
- PYUCVLVRHYGSER-UHFFFAOYSA-N n-[4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]piperidine-1-carboxamide Chemical compound CC1CCCN1C1CN(C=2C=CC(NC(=O)N3CCCCC3)=CC=2)CC1 PYUCVLVRHYGSER-UHFFFAOYSA-N 0.000 claims 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000037321 sleepiness Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98060607P | 2007-10-17 | 2007-10-17 | |
| US60/980,606 | 2007-10-17 | ||
| PCT/US2008/079763 WO2009052068A1 (en) | 2007-10-17 | 2008-10-14 | Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500697A JP2011500697A (ja) | 2011-01-06 |
| JP2011500697A5 true JP2011500697A5 (enExample) | 2011-12-01 |
| JP5380455B2 JP5380455B2 (ja) | 2014-01-08 |
Family
ID=40248052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530054A Expired - Fee Related JP5380455B2 (ja) | 2007-10-17 | 2008-10-14 | 置換されたｎ−フェニル−ビピロリジン尿素及びその治療上の使用 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8222290B2 (enExample) |
| EP (1) | EP2215058B1 (enExample) |
| JP (1) | JP5380455B2 (enExample) |
| KR (1) | KR20100082349A (enExample) |
| CN (1) | CN101903341B (enExample) |
| AT (1) | ATE534625T1 (enExample) |
| AU (1) | AU2008312641A1 (enExample) |
| CA (1) | CA2702933C (enExample) |
| CY (1) | CY1112391T1 (enExample) |
| DK (1) | DK2215058T3 (enExample) |
| ES (1) | ES2378011T3 (enExample) |
| HR (1) | HRP20120166T1 (enExample) |
| IL (1) | IL205002A0 (enExample) |
| MA (1) | MA31889B1 (enExample) |
| MX (1) | MX2010003948A (enExample) |
| MY (1) | MY148807A (enExample) |
| NZ (1) | NZ584692A (enExample) |
| PL (1) | PL2215058T3 (enExample) |
| PT (1) | PT2215058E (enExample) |
| RS (1) | RS52221B (enExample) |
| RU (1) | RU2478094C2 (enExample) |
| SI (1) | SI2215058T1 (enExample) |
| WO (1) | WO2009052068A1 (enExample) |
| ZA (1) | ZA201002114B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2372332T3 (es) | 2007-10-17 | 2012-01-18 | Sanofi | N-fenil-bipirrolidina carboxamidas sustituidas y su uso terapéutico. |
| SI2212282T1 (sl) * | 2007-10-17 | 2012-01-31 | Sanofi Sa | Substituirani n-fenil-bipirolidin karboksamidi in njihova terapevtska uporaba |
| WO2009052063A1 (en) | 2007-10-17 | 2009-04-23 | Sanofi-Aventis | Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators |
| KR20090129927A (ko) | 2008-06-13 | 2009-12-17 | 주식회사 엘지화학 | 발열체 및 이의 제조방법 |
| US10412788B2 (en) | 2008-06-13 | 2019-09-10 | Lg Chem, Ltd. | Heating element and manufacturing method thereof |
| US9611171B2 (en) | 2008-06-13 | 2017-04-04 | Lg Chem, Ltd. | Heating element and manufacturing method thereof |
| WO2011143155A1 (en) | 2010-05-11 | 2011-11-17 | Sanofi | Substituted n-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof |
| JP5968307B2 (ja) | 2010-05-11 | 2016-08-10 | サノフイ | 置換フェニルシクロアルキルピロリジン（ピペリジン）スピロラクタム類及びアミド類、それらの製造及び治療的使用 |
| EP2569294B1 (en) * | 2010-05-11 | 2015-03-11 | Sanofi | Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof |
| AR081382A1 (es) | 2010-05-11 | 2012-08-29 | Sanofi Aventis | Derivados de n-heterocicloalquil bipirrolidinilfenil amida sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central. |
| JP2013526530A (ja) * | 2010-05-11 | 2013-06-24 | サノフイ | 置換されたｎ−フェニルスピロラクタムビピロリジン、その製造及び治療上の使用 |
| TW201202251A (en) | 2010-05-11 | 2012-01-16 | Sanofi Aventis | Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof |
| WO2011143145A1 (en) | 2010-05-11 | 2011-11-17 | Sanofi | Substituted n-alkyl and n-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof |
| SG10201602857UA (en) * | 2010-11-15 | 2016-05-30 | Abbvie Inc | NAMPT And Rock Inhibitors |
| EP2694492B1 (en) * | 2011-02-23 | 2015-07-29 | Suven Life Sciences Limited | Novel compounds as histamine h3 receptor ligands |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020507A1 (es) * | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| US7279491B2 (en) * | 2002-10-23 | 2007-10-09 | Janssen Pharmaceutica N.V. | Phenylpiperidines and phenylpyrrolidines |
| DE10306250A1 (de) * | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US7223788B2 (en) * | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
| DE602006010833D1 (de) | 2005-03-17 | 2010-01-14 | Lilly Co Eli | Pyrrolidinderivate als histamin-h3-rezeptorantagonisten |
| AU2006232871B9 (en) * | 2005-04-01 | 2011-11-24 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
| WO2007005503A1 (en) * | 2005-07-01 | 2007-01-11 | Eli Lilly And Company | Histamine h3 receptor agents, preparation and therapeutic uses |
| TW200804274A (en) * | 2005-10-27 | 2008-01-16 | Ucb Sa | Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses |
| WO2009052063A1 (en) | 2007-10-17 | 2009-04-23 | Sanofi-Aventis | Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators |
| SI2212282T1 (sl) | 2007-10-17 | 2012-01-31 | Sanofi Sa | Substituirani n-fenil-bipirolidin karboksamidi in njihova terapevtska uporaba |
| ES2372332T3 (es) | 2007-10-17 | 2012-01-18 | Sanofi | N-fenil-bipirrolidina carboxamidas sustituidas y su uso terapéutico. |
-
2008
- 2008-10-14 NZ NZ584692A patent/NZ584692A/en not_active IP Right Cessation
- 2008-10-14 JP JP2010530054A patent/JP5380455B2/ja not_active Expired - Fee Related
- 2008-10-14 RS RS20120067A patent/RS52221B/sr unknown
- 2008-10-14 CN CN2008801212096A patent/CN101903341B/zh not_active Expired - Fee Related
- 2008-10-14 RU RU2010119554/04A patent/RU2478094C2/ru not_active IP Right Cessation
- 2008-10-14 WO PCT/US2008/079763 patent/WO2009052068A1/en not_active Ceased
- 2008-10-14 PT PT08838702T patent/PT2215058E/pt unknown
- 2008-10-14 HR HR20120166T patent/HRP20120166T1/hr unknown
- 2008-10-14 CA CA2702933A patent/CA2702933C/en not_active Expired - Fee Related
- 2008-10-14 DK DK08838702.2T patent/DK2215058T3/da active
- 2008-10-14 PL PL08838702T patent/PL2215058T3/pl unknown
- 2008-10-14 EP EP08838702A patent/EP2215058B1/en active Active
- 2008-10-14 MY MYPI2010001300A patent/MY148807A/en unknown
- 2008-10-14 SI SI200830552T patent/SI2215058T1/sl unknown
- 2008-10-14 ES ES08838702T patent/ES2378011T3/es active Active
- 2008-10-14 AU AU2008312641A patent/AU2008312641A1/en not_active Abandoned
- 2008-10-14 KR KR1020107010481A patent/KR20100082349A/ko not_active Ceased
- 2008-10-14 AT AT08838702T patent/ATE534625T1/de active
- 2008-10-14 MX MX2010003948A patent/MX2010003948A/es active IP Right Grant
-
2010
- 2010-03-15 US US12/724,045 patent/US8222290B2/en not_active Expired - Fee Related
- 2010-03-25 ZA ZA2010/02114A patent/ZA201002114B/en unknown
- 2010-04-11 IL IL205002A patent/IL205002A0/en unknown
- 2010-05-17 MA MA32842A patent/MA31889B1/fr unknown
-
2012
- 2012-02-23 CY CY20121100185T patent/CY1112391T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500697A5 (enExample) | ||
| CA2702933A1 (en) | Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof | |
| RU2010119530A (ru) | Замещенные n-фенилпирролидинилметилпирролидинамиды и их терапевтическое применение в качестве модуляторов рецептора н3 гистамина | |
| JP2011500694A5 (enExample) | ||
| JP2009541461A5 (enExample) | ||
| JP2011500696A5 (enExample) | ||
| JP2011524906A5 (enExample) | ||
| JP2005526723A5 (enExample) | ||
| JP2011500693A5 (enExample) | ||
| RU2010119560A (ru) | Замещенные n-фенилбипирролидинкарбоксамиды и их терапевтическое применение | |
| JP2006519258A5 (enExample) | ||
| NO341591B1 (no) | 3-Z-[1-(4-(N-((4-metyl-piperazin-1-yl)-metylkarbonyl)-N-metyl-amino)-anilino)-1-fenyl-metylen]-6-metoksykarbonyl-2-indolinon, tautomerene, diastereomerene, enantiomerene, blandinger derav og saltene derav, og i kombinasjon med en ytterligere farmakologisk aktiv substans, for anvendelse i forebygging eller behandling av fibrose ved revmatoid artritt | |
| RU2012129737A (ru) | Замещенные бензамидные производные | |
| NZ600716A (en) | Substituted isoquinolinones and quinazolinones | |
| PL2142193T3 (pl) | 1-[2-(2,4-demetylofenylosulfanylo)fenylo]piperazyna jako związek z połączonym wychwytem zwrotnym serotoniny, aktywnością względem 5HT3 i 5-HT1A do leczenia bólu lub rezydualnych objawów depresji związanych ze snem i procesami poznawczymi | |
| NO343929B3 (no) | 1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte | |
| JP2013517283A5 (enExample) | ||
| NZ603724A (en) | Piperidine derivatives and their use for the treatment of metabolic disorders | |
| CA2587800A1 (en) | Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| RU2010119528A (ru) | Замещенные n-фенилбипирролидинкарбоксамиды и их применение в лечебных целях | |
| JP2009527462A5 (enExample) | ||
| NZ617334A (en) | Cyclopropyl amine derivatives | |
| JP2009537542A5 (enExample) | ||
| JP2010500345A5 (enExample) | ||
| NZ598083A (en) | New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine |